Latest news with #AnnualConferenceof
Yahoo
20-05-2025
- Business
- Yahoo
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
Company's NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J., May 20, 2025--(BUSINESS WIRE)--CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world's top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop resistance mutations including the T790M gatekeeper mutation. Osimertinib, a 3rd-generation covalent TKI, is efficacious against the T790M resistance mutation and prevents its onset if administered as first line therapy. However, treatment with Osimertinib inevitably induces additional mutations, especially the C797S mutation, as well as various off-target resistance mechanisms. To date, there are no approved therapies capable of overcoming mutational or non-mutational resistance to 3rd-generation TKIs. As such, there is an urgent unmet medical need to develop next-generation EGFR inhibitors that overcome these forms of resistance. While billions of dollars have been invested over the last several years on the development of 4th-generation EGFR inhibitors that overcome tumor resistance to 3rd-generation inhibitors, due to the diversity of resistance mechanisms, these inhibitors have failed to progress beyond early-stage clinical trials. At ASCO 2025, CCM Biosciences' presentation "Novel, potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy" in the Lung Cancer – Non-small cell – Metastatic session (Abstract #: 8622, will report novel 4th-generation, orally bioavailable EGFR inhibitors (CCM-205, CCM-245 and CCM-308) that can overcome both on-target and off-target resistance in lung cancer models, significantly outperforming the aforementioned 4th-generation inhibitors in the face of resistance to 3rd-generation inhibitors, and have significant potential clinical applications. In addition to their potent activity as monotherapies, CCM-205 and CCM-245 are highly efficacious in combination with 3rd-generation EGFR inhibitors as well as anti-EGFR antibodies, neither of which can maintain or regress tumor volume in the presence of resistance as monotherapies. CCM Biosciences is advancing clinical candidates from its EGFR inhibitor program to investigational new drug (IND) filing this year for entry to clinical trials. The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 -- -- and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them. About CCM Biosciences CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue, enabling fully integrated drug discovery and development. View source version on Contacts Anisha Ghosh anisha@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
Company's NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J., May 20, 2025--(BUSINESS WIRE)--CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world's top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop resistance mutations including the T790M gatekeeper mutation. Osimertinib, a 3rd-generation covalent TKI, is efficacious against the T790M resistance mutation and prevents its onset if administered as first line therapy. However, treatment with Osimertinib inevitably induces additional mutations, especially the C797S mutation, as well as various off-target resistance mechanisms. To date, there are no approved therapies capable of overcoming mutational or non-mutational resistance to 3rd-generation TKIs. As such, there is an urgent unmet medical need to develop next-generation EGFR inhibitors that overcome these forms of resistance. While billions of dollars have been invested over the last several years on the development of 4th-generation EGFR inhibitors that overcome tumor resistance to 3rd-generation inhibitors, due to the diversity of resistance mechanisms, these inhibitors have failed to progress beyond early-stage clinical trials. At ASCO 2025, CCM Biosciences' presentation "Novel, potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy" in the Lung Cancer – Non-small cell – Metastatic session (Abstract #: 8622, will report novel 4th-generation, orally bioavailable EGFR inhibitors (CCM-205, CCM-245 and CCM-308) that can overcome both on-target and off-target resistance in lung cancer models, significantly outperforming the aforementioned 4th-generation inhibitors in the face of resistance to 3rd-generation inhibitors, and have significant potential clinical applications. In addition to their potent activity as monotherapies, CCM-205 and CCM-245 are highly efficacious in combination with 3rd-generation EGFR inhibitors as well as anti-EGFR antibodies, neither of which can maintain or regress tumor volume in the presence of resistance as monotherapies. CCM Biosciences is advancing clinical candidates from its EGFR inhibitor program to investigational new drug (IND) filing this year for entry to clinical trials. The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 -- -- and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them. About CCM Biosciences CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue, enabling fully integrated drug discovery and development. View source version on Contacts Anisha Ghosh anisha@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Al Etihad
31-03-2025
- Business
- Al Etihad
UAE set to host major global events in April
ABU DHABI (WAM)The United Arab Emirates is set to host a wide range of major conferences, exhibitions, and global events throughout April, reflecting its influential role in shaping the future of several vital sectors regionally and events hosted in the UAE are distinguished by broad international participation, further strengthening its position as the world's leading destination for business tourism and international conferences. AIM Congress 2025 Emergency and Crisis Management 2025The National Emergency Crisis and Disasters Management Authority is organising the 8th edition of the World Crisis & Emergency Management Summit 2025, which will take place from 8th to 9th April at ADNEC Abu Dhabi. The authority also announced the organisation of the "Crisis Management Technologies Exhibition" to run in parallel with the summit, aiming to showcase the UAE's leadership in fostering global partnerships, innovation, and the use of advanced technologies, with a focus on joint strategic initiatives that support preparedness and effective crisis response. Air Traffic ManagementAbu Dhabi will host the 64th edition of the Annual Conference of the International Federation of Air Traffic Controllers' Associations (IFATCA 2025) from 28th April to 2nd May, with extensive participation from international organisations, government agencies, and many leading companies in the civil aviation sector. Local ProductionThe 3rd edition of the World Local Production Forum will be held from 7th to 9th April at ADNEC, attracting over 4,000 participants. The forum will discuss key issues related to sustainable local production, technology transfer, and ways to enhance partnerships to ensure fair access to high-quality health products. Abu Dhabi Global Healthcare WeekThe Department of Health – Abu Dhabi is preparing to launch the second edition of Abu Dhabi Global Healthcare Week, taking place from 15th to 17th April 2025 at ADNEC. The event is expected to attract over 15,000 participants and more than 325 exhibiting entities. Culture Summit Abu DhabiThe Department of Culture and Tourism – Abu Dhabi is organising the 7th edition of its leading global platform, the Culture Summit Abu Dhabi, to be held from 27th to 29th April 2025 at Manarat Al Saadiyat in Abu Dhabi's cultural district. The summit will be held under the theme "Culture for Humanity and Beyond", and will spotlight the vital relationship between culture and humanity in a time of accelerated transformation. Global Justice, Love & Peace Summit AI WeekDubai AI Week will take place from 21st to 25th April 2025, featuring numerous conferences, initiatives, and exhibitions that reflect Dubai's vision for the future of AI and its vast opportunities. The event will host the third edition of the "Machines Can See" Summit and the Dubai AI Festival, which is expected to attract over 8,000 AI experts, more than 500 investors, and over 100 speakers and 100 exhibitors from more than 100 countries. Gaming and EsportsThe Dubai Festivals and Retail Establishment has announced the launch of the 4th edition of the Dubai Esports and Games Festival, the largest event of its kind in the region, taking place from 25th April to 11th May 2025. The festival will feature GameExpo, the GameExpo Summit, the Dubai Cosplay Championship, Play Beyond competitions, along with city-wide tournaments, educational challenges, and interactive experiences that allow visitors to explore and learn within the gaming world. Arabian Travel MarketThe next edition of the Arabian Travel Market (ATM) will be held at the Dubai World Trade Centre from 28th April to 1st May 2025. The event is expected to attract over 47,000 participants and will feature more than 2,600 exhibitors representing over 161 global destinations. Sharjah Children's Reading FestivalThe 16th edition of the Sharjah Children's Reading Festival will be held from 23rd April to 4th May 2025 at Expo Centre Sharjah. The festival will present a wide range of new book releases for children and youth, alongside a rich programme of interactive activities, theatrical and artistic performances, and educational and entertainment events lasting 12 days.
